Antiplatelet action of intravascular contrast media. Implications in diagnostic procedures.
The antiplatelet action of intravascular contrast media (CM) Renografin-76 (diatrizoate meglumine and diatrizoate sodium) was studied in vitro and in 21 patients undergoing radiodiagnostic procedures. In vitro studies suggested that in Renografin-76, meglumine was the chief constituent responsible for its antiplatelet action. In post-CM plasma from patients, clotting times were prolonged and platelet aggregation greatly impaired, albeit normal aggregation restored within 3 hours. Although changes in global clotting times and platelet aggregation were mostly transient, it is possible that CM usage in patients with thrombocytopenia, sickle cell phenomenon, and on anticoagulant-antiplatelet drugs may present a serious risk to their hemostatic integrity.
D000328:Adult; D000368:Aged; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects*; D003973:Diatrizoate / Q000633:toxicity*; D003974:Diatrizoate Meglumine / Q000633:toxicity; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D012306:Risk; D013997:Time Factors
D003973:Diatrizoate; D003974:Diatrizoate Meglumine; D005340:Fibrinogen